Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.
References
Mollenhauer, B. et al. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230–240 (2011).
Montine, T. J. et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682–2685 (2010).
Sonnen, J. A., Montine, K. S., Quinn, J. F., Breitner, J. C. & Montine, T. J. Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J. Alzheimers Dis. 19, 301–309 (2010).
Trojanowski, J. Q. et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6, 230–238 (2010).
Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59, 512–519 (2006).
Shi, M. et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570–580 (2011).
Mata, I. F. et al. SNCA variant associated with Parkinson disease and plasma α-synuclein level. Arch. Neurol. 67, 1350–1356 (2010).
Devic, I. et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain doi:10.1093/brain/awr015.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Montine, T. PD biomarkers—use of α-synuclein reaches new levels. Nat Rev Neurol 7, 308–309 (2011). https://doi.org/10.1038/nrneurol.2011.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.66
- Springer Nature Limited